Document Classification

Section Type: METHODS

Text: Participants were randomized to receive GH (starting dose, 30 micro g/kg, reduced to 20 micro g/kg, subcutaneously 3 times/wk) + sex steroids (women : transdermal estradiol, 100 micro g/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10 days of each 28-day cycle [HRT] ; men : testosterone enanthate, biweekly intramuscular injections of 100 mg) (n = 35) ; GH + placebo sex steroid (n = 30) ; sex steroid + placebo GH (n = 35) ; or placebo GH + placebo sex steroid (n = 31) in a 2 x 2 factorial design.